← All trials
NCT04235608
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 30, 2020
- Primary completion
- Apr 30, 2024
- Completion date
- Oct 30, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- 700
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University Clermont AuvergneLead sponsor
- University of MontpellierCollaborator
- University of LilleOverall official - principal investigator
- University of NantesOverall official - principal investigator
- University of BurgundyOverall official - principal investigator
- University of PoitiersOverall official - principal investigator
- University of Nice Sophia AntipolisOverall official - principal investigator
- University of AngersOverall official - principal investigator
- University of Picardie Jules VerneOverall official - principal investigator
- University of Western BrittanyOverall official - principal investigator
- University of StrasbourgOverall official - principal investigator
- University of ReimsOverall official - principal investigator
- University of RennesOverall official - principal investigator
- University Clermont AuvergneOverall official - principal investigator
- University Clermont AuvergneStudy chair
- Groupe Hospitalier Diaconesses Croix Saint SimonOverall official - principal investigator
- Groupe Hospitalier Bretagne SudOverall official - principal investigator
- University of NimesOverall official - principal investigator
- University of MontpellierOverall official - principal investigator
- Groupe Hospitalier Sud Ile-de-FranceOverall official - principal investigator
- CH DUNKERQUEOverall official - principal investigator
- Centre Hospitalier de DouaiStudy chair
- Centre Hospitalier de CannesOverall official - principal investigator
- Centre Hospitalier de Saint-BrieucOverall official - principal investigator
- Centre Hospitalier de BéthuneOverall official - principal investigator
- Centre Jean PerrinOverall official - principal investigator
- University of ParisOverall official - principal investigator
- University of ParisCollaborator
- Sorbonne UniversityOverall official - principal investigator
- CHU La TimoneOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.